Gigante, V. et al. Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps. Antimicrob. Agents Chemother. 68, e0053524 (2024).
GBD 2021 Antimicrobial Resistance Collaborators Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050. Lancet 404, 1199–1226 (2024).
Murray, C. J. et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399, 629–655 (2022).
Sati, H. et al. The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance. Lancet Infect. Dis. 25, 1033–1043 (2025).
Müller, C. et al. A global view on carbapenem-resistant Acinetobacter baumannii. mBio 14, e02260-23 (2023).
Wenzler, E., Goff, D. A., Humphries, R. & Goldstein, E. J. C. Anticipating the unpredictable: a review of antimicrobial stewardship and acinetobacter infections. Infect. Dis. Ther. 6, 149–172 (2017).
Bostanghadiri, N. et al. Prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis. Antimicrob. Resist. Infect. Control 13, 24 (2024).
Mohamed, Y. F., Abou-Shleib, H. M., Khalil, A. M., El-Guink, N. M. & El-Nakeeb, M. A. Membrane permeabilization of colistin toward pan-drug resistant Gram-negative isolates. Braz. J. Microbiol. 47, 381–388 (2016).
Sabnis, A. et al. Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane. eLife 10, 1–26 (2021).
Aghapour, Z. et al. Molecular mechanisms related to colistin resistance in Enterobacteriaceae. Infect. Drug Resist. 12, 965–975 (2019).
Moffatt, J. H. et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob. Agents Chemother. 54, 4971–4977 (2010).
Moffatt, J. H. et al. Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. Antimicrob. Agents Chemother. 55, 3022–3024 (2011).
Dahdouh, E. et al. A novel mutation in pmrB mediates colistin resistance during therapy of Acinetobacter baumannii. Int J. Antimicrob. Agents 49, 727–733 (2017).
Seleim, S. M., Mostafa, M. S., Ouda, N. H. & Shash, R. Y. The role of pmrCAB genes in colistin-resistant Acinetobacter baumannii. Sci. Rep. 12, 20951 (2022).
Lin, M.-F., Lin, Y.-Y. & Lan, C.-Y. Contribution of EmrAB efflux pumps to colistin resistance in Acinetobacter baumannii. J. Microbiol. 55, 130–136 (2017).
Tyers, M. & Wright, G. D. Drug combinations: a strategy to extend the life of antibiotics in the 21st century. Nat. Rev. Microbiol. 17, 141–155 (2019).
Shields, R. K. et al. High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. Diagn. Microbiol Infect. Dis. 70, 246–252 (2011).
Wareham, D. W. & Bean, D. C. In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann. Clin. Microbiol. Antimicrob. 5, 10 (2006).
Pankuch, G. A., Lin, G., Seifert, H. & Appelbaum, P. C. Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Antimicrob. Agents Chemother. 52, 333–336 (2008).
Guelfi, K. C. et al. In vitro evaluation of the antimicrobial activity of meropenem in combination with polymyxin B and gatifloxacin against Pseudomonas aeruginosa and Acinetobacter baumannii. J. Chemother. 20, 180–185 (2008).
Wang, X. et al. Colistin-phage combinations decrease antibiotic resistance in Acinetobacter baumannii via changes in envelope architecture. Emerg. Microbes Infect. 10, 2205–2219 (2021).
Sugrue, I., Ross, R. P. & Hill, C. Bacteriocin diversity, function, discovery and application as antimicrobials. Nat. Rev. Microbiol. 22, 556–571 (2024).
Soltani, S. et al. Bacteriocins as a new generation of antimicrobials: toxicity aspects and regulations. FEMS Microbiol. Rev. 45, fuaa039 (2021).
Telhig, S., Ben Said, L., Zirah, S., Fliss, I. & Rebuffat, S. Bacteriocins to Thwart Sbacterial resistance in gram negative bacteria. Front. Microbiol. 11, 586433 (2020).
Cotter, P. D., Ross, R. P. & Hill, C. Bacteriocins – A viable alternative to antibiotics? Nat. Rev. Microbiol 11, 95–105 (2013).
Naghmouchi, K. et al. Synergistic effect between colistin and bacteriocins in controlling Gram-negative pathogens and their potential to reduce antibiotic toxicity in mammalian epithelial cells. Antimicrob. Agents Chemother. 57, 2719–2725 (2013).
Chi, H. & Holo, H. Synergistic antimicrobial activity between the broad spectrum bacteriocin garvicin KS and nisin, farnesol and polymyxin B against gram-positive and gram-negative bacteria. Curr. Microbiol. 75, 272–277 (2018).
Thomas, V. M., Brown, R. M., Ashcraft, D. S. & Pankey, G. A. Synergistic effect between nisin and polymyxin B against pandrug-resistant and extensively drug-resistant Acinetobacter baumannii. Int. J. Antimicrob. Agents 53, 663–668 (2019).
Jahangiri, A. et al. Synergistic effect of two antimicrobial peptides, Nisin and P10 with conventional antibiotics against extensively drug-resistant Acinetobacter baumannii and colistin-resistant Pseudomonas aeruginosa isolates. Micro. Pathog. 150, 104700 (2021).
Brunati, C. et al. Expanding the potential of NAI-107 for treating serious ESKAPE pathogens: synergistic combinations against Gram-negatives and bactericidal activity against non-dividing cells. J. Antimicrob. Chemother. 73, 414–424 (2018).
Mortzfeld, B. M., Bhattarai, S. K. & Bucci, V. Novel class IIb microcins show activity against Gram-negative ESKAPE and plant pathogens. Elife 13, RP102912 (2024).
Valcek, A. et al. Phenotypic Characterization and Heterogeneity among Modern Clinical Isolates of Acinetobacter baumannii. Microbiol. Spectr. 11, e0306122 (2023).
Jacobs, A. C. et al. AB5075, a highly virulent isolate of acinetobacter baumannii, as a model strain for the evaluation of pathogenesis and antimicrobial treatments. mBio 5, 10–1128 (2014).
Ayoub Moubareck, C. & Hammoudi Halat, D. Insights into acinetobacter baumannii: a review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen. Antibiotics 9, 119 (2020).
Iwatani, S., Zendo, T., Yoneyama, F., Nakayama, J. & Sonomoto, K. Characterization and structure analysis of a novel bacteriocin, lacticin Z, produced by Lactococcus lactis QU 14. Biosci. Biotechnol. Biochem. 71, 1984–1992 (2007).
Cintas, L. M. et al. Enterocins L50A and L50B, two novel bacteriocins from Enterococcus faecium L50, are related to staphylococcal hemolysins. J. Bacteriol. 180, 1988–1994 (1998).
Yoneyama, F. et al. Lacticin Q-mediated selective toxicity depending on physicochemical features of membrane components. Antimicrob. Agents Chemother. 55, 2446–2450 (2011).
Hofkens, N. et al. Microbisporicin (NAI-107) protects Galleria mellonella from infection with Neisseria gonorrhoeae. Microbiol. Spectr. 11, e0282523 (2023).
Hofkens, N. et al. Protective effect of microbisporicin (NAI-107) against vancomycin resistant Enterococcus faecium infection in a Galleria mellonella model. Sci. Rep. 14, 4786 (2024).
Fujita, K. et al. Structural analysis and characterization of lacticin Q, a novel bacteriocin belonging to a new family of unmodified bacteriocins of gram-positive bacteria. Appl. Environ. Microbiol. 73, 2871–2877 (2007).
Liu, X. et al. Identification of an N-terminal formylated, two-peptide bacteriocin from Enterococcus faecalis 710C. J. Agric. Food Chem. 59, 5602–5608 (2011).
Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493–500 (2024).
Acedo, J. Z. et al. Nuclear magnetic resonance solution structures of lacticin Q and aureocin A53 reveal a structural motif conserved among leaderless bacteriocins with broad-spectrum activity. Biochemistry 55, 733–742 (2016).
Yoneyama, F. et al. Lacticin Q, a lactococcal bacteriocin, causes high-level membrane permeability in the absence of specific receptors. Appl. Environ. Microbiol 75, 538–541 (2009).
Yoneyama, F. et al. Peptide-lipid huge toroidal pore, a new antimicrobial mechanism mediated by a lactococcal bacteriocin, lacticin Q. Antimicrob. Agents Chemother. 53, 3211–3217 (2009).
Netz, D. J. A., Bastos, M., do, C., de, F. & Sahl, H.-G. Mode of action of the antimicrobial peptide aureocin A53 from Staphylococcus aureus. Appl. Environ. Microbiol. 68, 5274–5280 (2002).
Lopalco, P., Stahl, J., Annese, C., Averhoff, B. & Corcelli, A. Identification of unique cardiolipin and monolysocardiolipin species in Acinetobacter baumannii. Sci. Rep. 7, 2972 (2017).
Ushiyama, F. et al. Lead optimization of 2-hydroxymethyl imidazoles as non-hydroxamate LpxC inhibitors: discovery of TP0586532. Bioorg. Med. Chem. 30, 115964 (2021).
Yoshida, I., Takata, I., Fujita, K., Takashima, H. & Sugiyama, H. TP0586532, a novel non-hydroxamate LpxC inhibitor: potentiating effect on in vitro activity of meropenem against carbapenem-resistant Enterobacteriaceae. Microbiol. Spectr. 10, e0082822 (2022).
Simpson, B. W. et al. Acinetobacter baumannii can survive with an outer membrane lacking lipooligosaccharide due to structural support from elongasome peptidoglycan synthesis. mBio 12, e0309921 (2021).
Carretero-Ledesma, M. et al. Phenotypic changes associated with Colistin resistance due to Lipopolysaccharide loss in Acinetobacter baumannii. Virulence 9, 930–942 (2018).
Kamoshida, G. et al. Lipopolysaccharide-deficient Acinetobacter baumannii due to colistin resistance is killed by neutrophil-produced lysozyme. Front. Microbiol. 11, 573 (2020).
Powers, M. J. & Trent, M. S. Phospholipid retention in the absence of asymmetry strengthens the outer membrane permeability barrier to last-resort antibiotics. Proc. Natl. Acad. Sci. USA 115, E8518–E8527 (2018).
Beceiro, A. et al. Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii. Antimicrob. Agents Chemother. 58, 518–526 (2014).
Boll, J. M. et al. A penicillin-binding protein inhibits selection of colistin-resistant, lipooligosaccharide-deficient Acinetobacter baumannii. Proc. Natl. Acad. Sci. USA 113, E6228–E6237 (2016).
Hernandez-Bird, J. et al. Resistance, heteroresistance, and fitness costs drive colistin treatment failure during Acinetobacter baumannii pneumonia. Proc. Natl. Acad. Sci. USA 123, e2515303123 (2026).
Charretier, Y. et al. Colistin heteroresistance and involvement of the PmrAB regulatory system in Acinetobacter baumannii. Antimicrob. Agents Chemother. 62, e00788–18 (2018).
Yau, W. et al. Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J. Infect. 58, 138–144 (2009).
Andersson, D. I., Nicoloff, H. & Hjort, K. Mechanisms and clinical relevance of bacterial heteroresistance. Nat. Rev. Microbiol 17, 479–496 (2019).
Novović, K. & Jovčić, B. Colistin resistance in Acinetobacter baumannii: molecular mechanisms and epidemiology. Antibiotics 12, 516 (2023).
Veeraraghavan, B. et al. A microbiological and structural analysis of the interplay between sulbactam/durlobactam and imipenem against penicillin-binding proteins (PBPs) of Acinetobacter spp. Antimicrob. Agents Chemother. 69, e0162724 (2025).
Hashizume, T., Ishino, F., Nakagawa, J., Tamaki, S. & Matsuhashi, M. Studies on the mechanism of action of imipenem (N-formimidoylthienamycin) in vitro: binding to the penicillin-binding proteins (PBPs) in Escherichia coli and Pseudomonas aeruginosa, and inhibition of enzyme activities due to the PBPs in E. coli. J. Antibiot. 37, 394–400 (1984).
Atanaskovic, I. & Kleanthous, C. Tools and approaches for dissecting protein bacteriocin import in gram-negative bacteria. Front. Microbiol. 10, 646 (2019).
Tenaillon, O., Denamur, E. & Matic, I. Evolutionary significance of stress-induced mutagenesis in bacteria. Trends Microbiol. 12, 264–270 (2004).
Pribis, J. P., Zhai, Y., Hastings, P. J. & Rosenberg, S. M. Stress-induced mutagenesis, gambler cells, and stealth targeting antibiotic-induced evolution. mBio 13, e0107422 (2022).
Manuse, S. et al. Bacterial persisters are a stochastically formed subpopulation of low-energy cells. PLoS Biol. 19, e3001194 (2021).
Shan, Y. et al. ATP-dependent persister formation in Escherichia coli. mBio 8, e02267–16 (2017).
Edelmann, D. & Berghoff, B. A. A shift in perspective: a role for the type I toxin TisB as persistence-stabilizing factor. Front. Microbiol. 13, 871699 (2022).
MacNair, C. R. et al. Overcoming mcr-1 mediated colistin resistance with colistin in combination with other antibiotics. Nat. Commun. 9, 458 (2018).
Maharramov, E. et al. Exploring the principles behind antibiotics with limited resistance. Nat. Commun. 16, 1842 (2025).
Kaneti, G., Sarig, H., Marjieh, I., Fadia, Z. & Mor, A. Simultaneous breakdown of multiple antibiotic resistance mechanisms in S. aureus. FASEB J. 27, 4834–4843 (2013).
Stokes, J. M. et al. Pentamidine sensitizes Gram-negative pathogens to antibiotics and overcomes acquired colistin resistance. Nat. Microbiol 2, 17028 (2017).
Lázár, V. et al. Antibiotic-resistant bacteria show widespread collateral sensitivity to antimicrobial peptides. Nat. Microbiol 3, 718–731 (2018).
Blattner, F. R. et al. The complete genome sequence of Escherichia coli K-12. Science 277, 1453–1462 (1997).
Gabant, P. & Borrero, J. PARAGEN 1.0: a standardized synthetic gene library for fast cell-free bacteriocin synthesis. Front Bioeng. Biotechnol. 7, 213 (2019).
Lin, Y. et al. Assembly of long error-prone reads using de Bruijn graphs. Proc. Natl. Acad. Sci. USA 113, E8396–E8405 (2016).
Simão, F. A., Waterhouse, R. M., Ioannidis, P., Kriventseva, E. V. & Zdobnov, E. M. BUSCO: assessing genome assembly and annotation completeness with single-copy orthologs. Bioinformatics 31, 3210–3212 (2015).
Cuccuru, G. et al. Orione, a web-based framework for NGS analysis in microbiology. Bioinformatics 30, 1928–1929 (2014).
Feldgarden, M. et al. AMRFinderPlus and the Reference Gene Catalog facilitate examination of the genomic links among antimicrobial resistance, stress response, and virulence. Sci. Rep. 11, 12728 (2021).
Krawczyk, P. S., Lipinski, L. & Dziembowski, A. PlasFlow: predicting plasmid sequences in metagenomic data using genome signatures. Nucleic Acids Res 46, e35 (2018).
Perrin, A. & Rocha, E. P. C. PanACoTA: a modular tool for massive microbial comparative genomics. NAR Genom. Bioinform. 3, lqaa106 (2021).
Morrissey, I. & Patel, J. B. Modification of antimicrobial susceptibility testing methods. J. Antimicrob. Chemother. 80, 2887–2888 (2025).
Cannella, S. E. et al. Stability, structural and functional properties of a monomeric, calcium-loaded adenylate cyclase toxin, CyaA, from Bordetella pertussis. Sci. Rep. 7, 42065 (2017).
Voegele, A. et al. A high-affinity calmodulin-binding site in the CyaA toxin translocation domain is essential for invasion of eukaryotic cells. Adv. Sci. 8, 2003630 (2021).
Subrini, O. et al. Characterization of a membrane-active peptide from the Bordetella pertussis CyaA toxin. J. Biol. Chem. 288, 32585–32598 (2013).
Sadi, M. et al. B2LiVe, a label-free 1D-NMR method to quantify the binding of amphitropic peptides or proteins to membrane vesicles. Cell Rep. Methods 3, 100624 (2023).